Dora Dias-Santagata

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2957212/publications.pdf

Version: 2024-02-01

58 papers	5,123 citations	257450 24 h-index	189892 50 g-index
59 all docs	59 docs citations	59 times ranked	8746 citing authors

#	Article	IF	Citations
1	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung Cancer. Cancer Discovery, 2016, 6, 1118-1133.	9.4	919
2	Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 2015, 5, 713-722.	9.4	429
3	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature Genetics, 2014, 46, 161-165.	21.4	408
4	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Molecular Medicine, 2010, 2, 146-158.	6.9	370
5	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine, 2019, 25, 1415-1421.	30.7	359
6	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discovery, 2018, 8, 1529-1539.	9.4	342
7	The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy. Cell, 2014, 158, 564-578.	28.9	298
8	EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology, 2019, 37, 278-285.	1.6	286
9	Oncogenic PI3K mutations are as common asAKT1andSMOmutations in meningioma. Neuro-Oncology, 2016, 18, 649-655.	1.2	221
10	Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in HÃ¼rthle Cell Carcinoma. Cancer Cell, 2018, 34, 242-255.e5.	16.8	185
11	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas. Clinical Cancer Research, 2014, 20, 2898-2909.	7.0	146
12	Acquired Resistance to Crizotinib in NSCLC with MET ÂExon 14 Skipping. Journal of Thoracic Oncology, 2016, 11, 1242-1245.	1.1	140
13	Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastrointestinal Endoscopy, 2016, 83, 140-148.	1.0	119
14	Activation of PI3K Signaling in Merkel Cell Carcinoma. Clinical Cancer Research, 2012, 18, 1227-1236.	7.0	97
15	Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy. Journal of Molecular Diagnostics, 2016, 18, 124-130.	2.8	79
16	Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. Human Pathology, 2019, 83, 50-58.	2.0	70
17	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clinical Cancer Research, 2020, 26, 1877-1885.	7.0	67
18	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discovery, 2018, 8, 417-427.	9.4	61

#	Article	IF	Citations
19	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. Npj Precision Oncology, 2017, 1, 5.	5.4	49
20	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head and Neck, 2022, 44, 1277-1300.	2.0	41
21	Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget, 2015, 6, 42445-42467.	1.8	40
22	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2015, 17, 661-668.	2.8	31
23	Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization. Human Pathology, 2019, 93, 65-73.	2.0	27
24	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clinical Cancer Research, 2019, 25, 4375-4387.	7.0	26
25	BRAF^{V600E} Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence. World Journal of Surgery, 2020, 44, 2685-2691.	1.6	26
26	Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. Thyroid, 2020, 30, 1384-1389.	4.5	25
27	Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. Endocrine Pathology, 2021, 32, 327-335.	9.0	25
28	Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Human Pathology, 2019, 86, 1-11.	2.0	24
29	Clear Cell Change in Thyroid Carcinoma: A Clinicopathologic and Molecular Study with Identification of Variable Genetic Anomalies. Thyroid, 2017, 27, 819-824.	4.5	21
30	Mucoacinar Carcinoma. American Journal of Surgical Pathology, 2021, 45, 1028-1037.	3.7	20
31	Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Oncologist, 2019, 24, 1356-1367.	3.7	18
32	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	17
33	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	17
34	De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naÃ¯ve ALK rearranged lung cancers. Lung Cancer, 2016, 99, 17-22.	2.0	16
35	Primary Benign and Malignant Thyroid Neoplasms With Signet Ring Cells. American Journal of Clinical Pathology, 2017, 148, 251-258.	0.7	16
36	Artificial Intelligence Approach for Variant Reporting. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	2.1	13

#	Article	IF	Citations
37	Merkel Cell Carcinoma of Unknown Primary: Immunohistochemical and Molecular Analyses Reveal Distinct UV-Signature/MCPyV-Negative and High Immunogenicity/MCPyV-Positive Profiles. Cancers, 2021, 13, 1621.	3.7	10
38	Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancerâ€“Transformed EGFR Mutant Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 1, 1-7.	3.0	8
39	Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation. Oncologist, 2018, 23, 650-653.	3.7	8
40	Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas. Cells, 2021, 10, 2216.	4.1	8
41	Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2029-2029.	1.6	7
42	Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma. International Journal of Molecular Sciences, 2022, 23, 4322.	4.1	7
43	Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis. Endocrine-Related Cancer, 2015, 22, L23-L28.	3.1	5
44	Intraductal carcinoma of the salivary gland with NCOA4-RET: expanding the morphologic spectrum and an algorithmic diagnostic approach. Human Pathology, 2021, 114, 74-89.	2.0	5
45	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Advances, 2022, 6, 818-827.	5.2	5
46	Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2017, 35, 1046-1046.	1.6	4
47	Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasisâ€”A case report. International Journal of Surgery Case Reports, 2017, 38, 180-184.	0.6	3
48	Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2018, 36, 8573-8573.	1.6	1
49	A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naÃ¯ve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8083-8083.	1.6	1
50	Characteristics of NSCLCs harboring NRAS mutations.. Journal of Clinical Oncology, 2012, 30, 7532-7532.	1.6	0
51	Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma. Blood, 2012, 120, 3990-3990.	1.4	0
52	The role of molecular profiling to differentiate multiple lung primary adenocarcinomas from intrapulmonary metastases from a lung primary.. Journal of Clinical Oncology, 2013, 31, 7555-7555.	1.6	0
53	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. Journal of Clinical Oncology, 2013, 31, 533-533.	1.6	0
54	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. Journal of Clinical Oncology, 2013, 31, 145-145.	1.6	0

#	Article	IF	Citations
55	Targetable signaling pathway mutations and progression of IDH-mutant glioma.. Journal of Clinical Oncology, 2014, 32, 2061-2061.	1.6	0
56	The feasibility to use minimal tumor samples for mutation analysis by multiplex PCR-based assay.. Journal of Clinical Oncology, 2014, 32, e22060-e22060.	1.6	0
57	Multi-institutional multiplexed genetic analysis in lung adenocarcinoma (AC): The Lung Cancer Mutation Consortium (LCMC I) experience.. Journal of Clinical Oncology, 2014, 32, 11030-11030.	1.6	0
58	Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with ESR1 mutations and fusions. Cancer Research, 2022, 82, 5248-5248.	0.9	0